Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 59-61
DOI: 10.58347/tml.2026.1752b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026.
Abstract (Originalsprache)
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia. The Medical Letter on Drugs and Therapeutics, 68(1752), 59-61. https://doi.org/10.58347/tml.2026.1752b
Vancouver
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):59-61. doi:10.58347/tml.2026.1752b
BibTeX
@article{euvimed2026,
title = {Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1752},
pages = {59--61},
doi = {10.58347/tml.2026.1752b}
}
EUVIMED